Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Burkitt Lymphoma 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Lymphoma, B-Cell 2Oropharyngeal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1HIV Infections 1Enteropathy-Associated T-Cell Lymphoma 1Cranial Nerve Diseases 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 5romidepsin 4pembrolizumab 4Lenalidomide 4Etoposide 410-propargyl-10-deazaaminopterin 4Rituximab 3fludarabine phosphate 2fludarabine 2durvalumab 2carmustine, poliferprosan 20 drug combination 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Melphalan 2Gemcitabine 2Doxorubicin 2Depsipeptides 2Cytarabine 2Carmustine 2Bendamustine Hydrochloride 2AFM13 2veliparib 1thymoglobulin 1tenalisib 1temsirolimus 1prednylidene 1mogamulizumab 1forodesine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell × prednylidene × Clear all
NCT02561273 2023-12-13

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

University of Nebraska

Phase 1/2 Completed
54 enrolled 14 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡